Splanchnic venous thrombosis
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-22 — Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study.: 2026 — Large US retrospective claims analysis (n=11,311 PV patients) documented high ongoing thromboembolic event rates (including splanchnic and other venous events) despite standard phlebotomy/cytoreduction, with most patients failing to maintain HCT <45% and substantial post-TE cost burden. (novelty: 3)
Open questions
Related
Contributing findings
Masked polycythaemia vera presenting with extensive splanchnic venous thrombosis and mesenteric ischaemia.
30-sep-2026
novelty 2
per-area 2
strengthens
Managing thrombotic risk in myeloproliferative disorders.
12-sep-2026
novelty 1
per-area 2
strengthens
Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera.
08-sep-2026
novelty 3
per-area 1
mentions
Malondialdehyde at the Crossroads of Oxidative Stress, Lipid Peroxidation, Ferroptosis, and Hematological Malignancies: A Narrative Review.
15-aug-2026
novelty 2
per-area 1
mentions
Adolescent and Young Adult versus Older Adult Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Center Experience from the MENA Region.
10-aug-2026
novelty 2
per-area 2
mentions
Dengue Fever Unmasking JAK2 Mutation-Related Polycythemia Vera Presenting With Extensive Splanchnic Venous Thrombosis and Hemorrhagic Complications: A Diagnostic and Therapeutic Challenge.
25-jul-2026
novelty 2
per-area 2
strengthens
Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study.
22-jul-2026
novelty 3
per-area 3
strengthens
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.
13-jul-2026
novelty 3
per-area 2
mentions
Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis.
01-jul-2026
novelty 1
per-area 1
mentions
Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review.
11-jun-2026
novelty 2
per-area 2
strengthens
Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.
05-feb-2026
novelty 2
per-area 1
mentions